{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:03:47Z","timestamp":1792688627736,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P01 HD112215"],"award-info":[{"award-number":["P01 HD112215"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P01 HD112215"],"award-info":[{"award-number":["P01 HD112215"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["K24 AI120796"],"award-info":[{"award-number":["K24 AI120796"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00751-2","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:50:39Z","timestamp":1755244239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-Acting Injectable Antiretroviral Drugs for Pregnant and Breastfeeding Women: Current Advances, Challenges, and Future Directions"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-1499","authenticated-orcid":false,"given":"Friday","family":"Saidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"2","key":"751_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/COH.0000000000000527","volume":"14","author":"M Vitoria","year":"2019","unstructured":"Vitoria M, Rangaraj A, Ford N, Doherty M. Current and future priorities for the development of optimal HIV drugs. Curr Opin HIV AIDS. 2019;14(2):143\u20139. https:\/\/doi.org\/10.1097\/COH.0000000000000527.","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"751_CR2","doi-asserted-by":"publisher","first-page":"e0295046","DOI":"10.1371\/journal.pone.0295046","volume":"18","author":"A Buh","year":"2023","unstructured":"Buh A, Deonandan R, Gomes J, Krentel A, Oladimeji O, Yaya S. Barriers and facilitators for interventions to improve ART adherence in Sub-Saharan African countries: A systematic review and meta-analysis. PLoS ONE. 2023;18(11):e0295046. https:\/\/doi.org\/10.1371\/journal.pone.0295046.","journal-title":"PLoS ONE"},{"issue":"13","key":"751_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Karim QA, et al. Twice-Yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2407001.","journal-title":"N Engl J Med"},{"issue":"12","key":"751_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, et al. Long-Acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1909512.","journal-title":"N Engl J Med"},{"issue":"10","key":"751_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/S1473-3099(24)00296-2","volume":"24","author":"C Orkin","year":"2024","unstructured":"Orkin C, Ring K. Implementing long-acting injectable cabotegravir and rilpivirine in Africa. Lancet Infect Dis. 2024;24(10):1060\u20131. https:\/\/doi.org\/10.1016\/S1473-3099(24)00296-2.","journal-title":"Lancet Infect Dis"},{"issue":"10337","key":"751_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet Lond Engl. 2022;399(10337):1779\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(22)00538-4.","journal-title":"Lancet Lond Engl"},{"key":"751_CR7","doi-asserted-by":"publisher","unstructured":"Erlwanger A, Rocroi I, Kirtley S, Hemelaar J. Perinatal outcomes associated with pre-exposure prophylaxis for HIV prevention during pregnancy: a systematic review and meta-analysis. eClinicalMedicine. 2024;70. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102532.","DOI":"10.1016\/j.eclinm.2024.102532"},{"issue":"9","key":"751_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","volume":"35","author":"AG Cutrell","year":"2021","unstructured":"Cutrell AG, Schapiro JM, Perno CF, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS Lond Engl. 2021;35(9):1333\u201342. https:\/\/doi.org\/10.1097\/QAD.0000000000002883.","journal-title":"AIDS Lond Engl"},{"issue":"1","key":"751_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.4102\/sajhivmed.v24i1.1497","volume":"24","author":"C Pike","year":"2023","unstructured":"Pike C, Rousseau E, Bekker LG. Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis. South Afr J HIV Med. 2023;24(1):1497. https:\/\/doi.org\/10.4102\/sajhivmed.v24i1.1497.","journal-title":"South Afr J HIV Med"},{"issue":"7","key":"751_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"N Engl J Med"},{"key":"751_CR11","unstructured":"Guidelines on long-acting injectable cabotegravir for HIV prevention. Accessed March 12. 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240054097"},{"key":"751_CR12","unstructured":"Rilpivirine Uses S, Effects, Warnings. Drugs.com. Accessed March 13, 2025. https:\/\/www.drugs.com\/mtm\/rilpivirine.html"},{"key":"751_CR13","unstructured":"ViiV Healthcare. ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment. Accessed March 13. 2025. https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2022\/january\/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months\/"},{"key":"751_CR14","unstructured":"SUNLENCA\u00ae (lenacapavir) Dosing and Administration, editor. Accessed March 13, 2025. https:\/\/www.sunlencahcp.com\/dosing-and-administration\/sunlenca-dosing\/"},{"key":"751_CR15","doi-asserted-by":"publisher","unstructured":"Margot N, Vanderveen L, Naik V,  Ram R, Parvangada PC, Martin R et al. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-conceptclinical study. J Antimicrob Chemother. 2022;77(4):989\u2013995. https:\/\/doi.org\/10.1093\/jac\/dkab503","DOI":"10.1093\/jac\/dkab503"},{"key":"751_CR16","doi-asserted-by":"publisher","unstructured":"Jogiraju V, Pawar P, Yager J, et al. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet. 2025;0(0). https:\/\/doi.org\/10.1016\/S0140-6736(25)00405-2.","DOI":"10.1016\/S0140-6736(25)00405-2"},{"key":"751_CR17","unstructured":"Ravula Tulasi Naga pavan kumar; Panja Aishwarya Sai, Sri PS. Boddani Sunil. Lenacapavir: A Novel Capsid Inhibitor in HIV-1 Treatment and Capsid Inhibitors Drugs. Accessed March 30, 2025. https:\/\/www.ijpsjournal.com\/article\/Lenacapavir+A+Novel+Capsid+Inhibitor+in+HIV1+Treatment+and+Capsid+Inhibitors+Drugs"},{"key":"751_CR18","doi-asserted-by":"publisher","unstructured":"Ding D, Shi D, Xu S, et al. Chapter 18 - Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatment of multidrug-resistant HIV infections. In: Yu B, Zhan P, editors. Drug discovery stories. Elsevier; 2025. pp. 341\u20139. https:\/\/doi.org\/10.1016\/B978-0-443-23932-8.00018-2.","DOI":"10.1016\/B978-0-443-23932-8.00018-2"},{"key":"751_CR19","doi-asserted-by":"publisher","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL et al. Twice-Yearly Lenacapavir for HIV prevention in men and Gender-Diverse persons. N Engl J Med. 0(0). https:\/\/doi.org\/10.1056\/NEJMoa2411858","DOI":"10.1056\/NEJMoa2411858"},{"key":"751_CR20","unstructured":"Gill K, Ndlovu N, Brumskine W, Jaggernath M, Zwane Z, Zhao Y et al. Lenacapavir pharmacokinetics, safety, and efficacy in adolescents and adults in PURPOSE 1. Conference on Retroviruses and Opportunistic Infections; 9\u201312 March; San Francisco, California, 2025.https:\/\/www.purposestudies.com\/"},{"key":"751_CR21","unstructured":"Mullen J, FDA Approves New Injection For HIV Prevention. 1750348800. Accessed June 19, 2025. https:\/\/www.msn.com\/en-us\/money\/general\/fda-approves-new-injection-for-hiv-prevention\/ar-AA1H2LWT?ocid=BingNewsSerp"},{"key":"751_CR22","unstructured":"World Health Organization. WHO announces the development of new guidelines for lenacapavir and updated HIV testing guidelines. Accessed March 13. 2025. https:\/\/www.who.int\/news\/item\/06-01-2025-who-announces-the-development-of-new-guidelines-for-lenacapavir-and-updated-hiv-testing-guidelines"},{"issue":"1","key":"751_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12884-025-07156-4","volume":"25","author":"N Li","year":"2025","unstructured":"Li N, Wen S, Zhu F, Liu G, Zhu D. Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report. BMC Pregnancy Childbirth. 2025;25(1):61. https:\/\/doi.org\/10.1186\/s12884-025-07156-4.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"24","key":"751_CR24","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","volume":"133","author":"B Su","year":"2020","unstructured":"Su B, Yao C, Zhao QX, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919\u201327. https:\/\/doi.org\/10.1097\/CM9.0000000000001273.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"751_CR25","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","volume":"7","author":"D Sch\u00fcrmann","year":"2020","unstructured":"Sch\u00fcrmann D, Rudd DJ, Zhang S, et al. Safety, pharmacokinetics, and antiretroviral activity of Islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. Lancet HIV. 2020;7(3):e164\u201372. https:\/\/doi.org\/10.1016\/S2352-3018(19)30372-8.","journal-title":"Lancet HIV"},{"issue":"10","key":"751_CR26","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3018(24)00173-5","volume":"11","author":"WDF Venter","year":"2024","unstructured":"Venter WDF, Gandhi M, Sokhela S, et al. The long wait for long-acting HIV prevention and treatment formulations. Lancet HIV. 2024;11(10):e711\u20136. https:\/\/doi.org\/10.1016\/S2352-3018(24)00173-5.","journal-title":"Lancet HIV"},{"key":"751_CR27","unstructured":"Izzat T. Raheem; Kerry Fillgrove; Gregory O\u00e2\u20acTMDonnell; Jonathan Patteson; Shih Lin Goh; Carolyn Bahnck-Teets; Qian Huang; Ernest Asante-Appiah; Min Xu; Steve S. Carroll; Jay A. Grobler; Jeffrey Hale; Ming-Tain Lai; Vinay Girijavallabhan; Tracy L. Diamond Merck & Co., Inc., Rahway, NJ, USA. Discovery of MK-8527, a long-acting HIV nucleoside reverse transcriptase translocation inhibitor. Accessed March 20, 2025. https:\/\/www.natap.org\/2024\/CROI\/croi_07.htm"},{"key":"751_CR28","unstructured":"Keith Alcorn. Once-weekly combination of islatravir and lenacapavir safe and effective in 48-week study. https:\/\/www.eatg.org\/. Accessed March 13, 2025. https:\/\/www.eatg.org\/"},{"issue":"1","key":"751_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","volume":"22","author":"S Mahomed","year":"2025","unstructured":"Mahomed S, Pillay K, Hassan-Moosa R, et al. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review. AIDS Res Ther. 2025;22(1):44. https:\/\/doi.org\/10.1186\/s12981-025-00734-8.","journal-title":"AIDS Res Ther"},{"issue":"Suppl 2","key":"751_CR30","doi-asserted-by":"publisher","first-page":"e25916","DOI":"10.1002\/jia2.25916","volume":"25","author":"EJ Abrams","year":"2022","unstructured":"Abrams EJ, Calmy A, Fairlie L, et al. Approaches to accelerating the study of new antiretrovirals in pregnancy. J Int AIDS Soc. 2022;25(Suppl 2):e25916. https:\/\/doi.org\/10.1002\/jia2.25916.","journal-title":"J Int AIDS Soc"},{"key":"751_CR31","unstructured":"PHASES: Pregnancy & HIV\/AIDS: Seeking Equitable Study. Accessed March 20, 2025. http:\/\/www.hivpregnancyethics.org"},{"issue":"4","key":"751_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/QAD.0000000000003803","volume":"38","author":"LF Johnson","year":"2024","unstructured":"Johnson LF, Myer L, Jamieson L, Meyer-Rath G, Delany-Moretlwe S, Joseph Davey D. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS Lond Engl. 2024;38(4):589\u201394. https:\/\/doi.org\/10.1097\/QAD.0000000000003803.","journal-title":"AIDS Lond Engl"},{"key":"751_CR33","unstructured":"Delany-Moretlwe S et al. Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension. International AIDS Conference. Thursday, July 25, 2024."},{"issue":"1","key":"751_CR34","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1186\/s12889-024-20029-3","volume":"24","author":"F Saidi","year":"2024","unstructured":"Saidi F, Shah S, Squibb M, et al. Evaluating the impact of HIV pre-exposure prophylaxis on pregnancy, infant, and maternal health outcomes in malawi: primo study protocol. BMC Public Health. 2024;24(1):2604. https:\/\/doi.org\/10.1186\/s12889-024-20029-3.","journal-title":"BMC Public Health"},{"key":"751_CR35","unstructured":"Bekker L-G, Moodley D, Harkoo I, Kigozi G, Louw CE, Malahleha M et al. Inclusion of pregnant and lactating people in thePURPOSE 1 study: efficacy, safety, and pharmacokinetics. 13th International AIDS Society Conference on HIV Science; 12\u201317 July; Kigali, Rwanda,2025. In: ; :34. https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jia2.26518"},{"key":"751_CR36","unstructured":"ViiV Healthcare. Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus). ctv.veeva.com. Accessed June 19. 2025. https:\/\/ctv.veeva.com\/study\/long-term-follow-up-of-long-acting-cabotegravir-cab-la-for-prep-pre-exposure-prophylaxis-in-part"},{"key":"751_CR37","unstructured":"Zash R. Linking HIV Prevention and Postpartum Care: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a High-Risk Breastfeeding Population in Botswana. clinicaltrials.gov; 2024. Accessed March 13, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05986084"},{"issue":"11","key":"751_CR38","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2352-3018(24)00235-2","volume":"11","author":"MR Kamya","year":"2024","unstructured":"Kamya MR, Balzer LB, Ayieko J, et al. Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and kenya: a randomised trial extension. Lancet HIV. 2024;11(11):e736\u201345. https:\/\/doi.org\/10.1016\/S2352-3018(24)00235-2.","journal-title":"Lancet HIV"},{"key":"751_CR39","unstructured":"Camlin CS. et.al. Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study| IAS Plus. Accessed March 21, 2025. https:\/\/plus.iasociety.org\/e-posters\/early-experiences-usage-injectable-cabotegravir-cab-la-among-kenyan-and-ugandan-adults"},{"key":"751_CR40","unstructured":"Blantyre Prevention Strategy. Expanding service delivery for current prevention tools and improving introduction and scale-up of cutting-edge like injectable PrEP. BPS. Accessed March 21. 2025. https:\/\/www.blantyrepreventionstrategy.com\/expanding-service-delivery"},{"key":"751_CR41","unstructured":"Holmes C. Accelerating the Path To Scale for Injectable PrEP in Malawi: An Implementation Evaluation. clinicaltrials.gov; 2024. Accessed April 4, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06319105"},{"key":"751_CR42","unstructured":"Desmond Tutu HIV, Foundation. PrEPared to Choose (PtC): An Implementation Study of the Delivery of Cabotegravir Long-Acting Injectable Pre-Exposure Prophylaxis (PrEP) As an HIV Prevention Product Option Within a PrEP Choice Context in a Real World Setting in Cape Town. clinicaltrials.gov; 2025. Accessed March 30, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06807736"},{"key":"751_CR43","unstructured":"CATALYST, PrEPWatch. Accessed March 30, 2025. https:\/\/www.prepwatch.org\/catalyst\/"},{"key":"751_CR44","unstructured":"PURPOSE Studies. PURPOSE Studies. Accessed March 13, 2025. https:\/\/www.purposestudies.com\/"},{"issue":"12","key":"751_CR45","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-Acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1904398.","journal-title":"N Engl J Med"},{"issue":"10267","key":"751_CR46","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet Lond Engl. 2021;396(10267):1994\u20132005. https:\/\/doi.org\/10.1016\/S0140-6736(20)32666-0.","journal-title":"Lancet Lond Engl"},{"key":"751_CR47","doi-asserted-by":"publisher","unstructured":"Kityo C, Mambule IK, Musaazi J, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults withHIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024;24(10):1083\u20131092. https:\/\/doi.org\/10.1016\/S1473-3099(24)00289-5","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"751_CR48","unstructured":"Cresswell FV et al. Long-acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub-Saharan Africa: theIMPALA trial 48-week results. IAS 2025, 13\u201316 July 2025, Kigali, Rwanda. Oral late-breaker abstract OAS0105LBP.https:\/\/programme.ias2025.org\/Abstract\/Abstract\/?abstractid=6781"},{"key":"751_CR49","unstructured":"IMPAACT 2040. Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy (CREATE Study). Accessed March 13. 2025. https:\/\/www.impaactnetwork.org\/studies\/impaact2040"},{"issue":"9","key":"751_CR50","doi-asserted-by":"publisher","first-page":"e26003","DOI":"10.1002\/jia2.26003","volume":"25","author":"M Czarnogorski","year":"2022","unstructured":"Czarnogorski M, Garris CP, Dalessandro M, et al. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a hybrid III Implementation-effectiveness study (CUSTOMIZE). J Int AIDS Soc. 2022;25(9):e26003. https:\/\/doi.org\/10.1002\/jia2.26003.","journal-title":"J Int AIDS Soc"},{"key":"751_CR51","unstructured":"Wit SD, Rami A, Bonnet F et al. CARISEL: A Hybrid Type III Implementation Effectiveness Study of Implementation of Cabotegravir\u2009+\u2009Rilpivirine Long-Acting (CAB\u2009+\u2009RPV LA) in European Health Care Settings; Key Clinical and Implementation Outcomes by Implementation Arm."},{"issue":"1","key":"751_CR52","doi-asserted-by":"publisher","first-page":"e26401","DOI":"10.1002\/jia2.26401","volume":"28","author":"S Delany-Moretlwe","year":"2025","unstructured":"Delany-Moretlwe S, Hanscom B, Guo X, et al. Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in Eastern and Southern africa: a secondary analysis of HPTN 084. J Int AIDS Soc. 2025;28(1):e26401. https:\/\/doi.org\/10.1002\/jia2.26401.","journal-title":"J Int AIDS Soc"},{"key":"751_CR53","unstructured":"World Health Organization. WHO implementation tool for pre-exposure prophylaxis of HIV infection: provider module for oral and long-acting PrEP. Accessed July 21, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240097230"},{"issue":"5","key":"751_CR54","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/hiv.13439","volume":"24","author":"P Patel","year":"2023","unstructured":"Patel P, Ford SL, Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 2023;24(5):568\u201379. https:\/\/doi.org\/10.1111\/hiv.13439.","journal-title":"HIV Med"},{"key":"751_CR55","unstructured":"Short W et al. Long-Acting CAB\/RPV in Pregnancy - US."},{"issue":"6","key":"751_CR56","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/cid\/ciae242","volume":"79","author":"L van der Wekken-Pas","year":"2024","unstructured":"van der Wekken-Pas L, Weiss F, Simon-Zuber C, et al. Long-Acting injectable cabotegravir and rilpivirine in a pregnant woman with HIV. Clin Infect Dis Off Publ Infect Dis Soc Am. 2024;79(6):1468\u201371. https:\/\/doi.org\/10.1093\/cid\/ciae242.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"751_CR57","unstructured":"World Health Organization. Preventing HIV during pregnancy and breastfeeding in the context of PrEP. Accessed July 20. 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2017.09"},{"key":"751_CR58","doi-asserted-by":"crossref","unstructured":"Parker B, Ward T, Hayward O, Jacob I, Arthurs E et al. (2021). Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study| PLOS One. Accessed March 22, 2025. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0245955","DOI":"10.1371\/journal.pone.0245955"},{"key":"751_CR59","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/IJWH.S330715","volume":"14","author":"AE Njom Nlend","year":"2022","unstructured":"Njom Nlend AE. Mother-to-Child transmission of HIV through breastfeeding improving awareness and education: A short narrative review. Int J Womens Health. 2022;14:697\u2013703. https:\/\/doi.org\/10.2147\/IJWH.S330715.","journal-title":"Int J Womens Health"},{"key":"751_CR60","unstructured":"Simals S, Long-Acting ART, World News. May Prevent Infant HIV Infections in Zimbabwe. ODRi Media News - Breaking News, East Africa News, Sports News, Kenya News,. March 17, 2025. Accessed March 22, 2025. https:\/\/www.odrimedia.co.ke\/health\/long-acting-art-may-prevent-infant-hiv-infections-in-zimbabwe\/"},{"key":"751_CR61","unstructured":"Tewari S et al. Modeling impact and Cost-Effectiveness of Long-Acting CAB\/RPV in breastfeeding Women - Zimbabwe. In:; 2025."},{"issue":"5","key":"751_CR62","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/S2214-109X(21)00025-5","volume":"9","author":"AN Phillips","year":"2021","unstructured":"Phillips AN, Bansi-Matharu L, Cambiano V, et al. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan africa: a modelling analysis. Lancet Glob Health. 2021;9(5):e620\u20137. https:\/\/doi.org\/10.1016\/S2214-109X(21)00025-5.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"751_CR63","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","volume":"10","author":"J Smith","year":"2023","unstructured":"Smith J, Bansi-Matharu L, Cambiano V, et al. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan africa: a modelling study. Lancet HIV. 2023;10(4):e254\u201365. https:\/\/doi.org\/10.1016\/S2352-3018(22)00365-4.","journal-title":"Lancet HIV"},{"issue":"2","key":"751_CR64","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hiv.13370","volume":"24","author":"R D\u2019Amico","year":"2023","unstructured":"D\u2019Amico R, Cenoz Gomis S, Moodley R, et al. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy. HIV Med. 2023;24(2):202\u201311. https:\/\/doi.org\/10.1111\/hiv.13370.","journal-title":"HIV Med"},{"issue":"5","key":"751_CR65","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0000000000002487","volume":"34","author":"LA Graybill","year":"2020","unstructured":"Graybill LA, Kasaro M, Freeborn K, et al. Incident HIV among pregnant and breast-feeding women in sub-Saharan africa: a systematic review and meta-analysis. AIDS Lond Engl. 2020;34(5):761\u201376. https:\/\/doi.org\/10.1097\/QAD.0000000000002487.","journal-title":"AIDS Lond Engl"},{"issue":"5","key":"751_CR66","doi-asserted-by":"publisher","first-page":"e26088","DOI":"10.1002\/jia2.26088","volume":"26","author":"NJ Wara","year":"2023","unstructured":"Wara NJ, Mvududu R, Marwa MM, et al. Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya. J Int AIDS Soc. 2023;26(5):e26088. https:\/\/doi.org\/10.1002\/jia2.26088.","journal-title":"J Int AIDS Soc"},{"key":"751_CR67","doi-asserted-by":"publisher","first-page":"ihaf016","DOI":"10.1093\/inthealth\/ihaf016","volume":"13","author":"D Ekusai-Sebatta","year":"2025","unstructured":"Ekusai-Sebatta D, Namugenyi RS, Laker E, et al. Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa. Int Health Published Online March. 2025;13:ihaf016. https:\/\/doi.org\/10.1093\/inthealth\/ihaf016.","journal-title":"Int Health Published Online March"},{"key":"751_CR68","doi-asserted-by":"publisher","unstructured":"Heather Watts D. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV\/AIDS Rep. 2007;4(3):135\u2013140. https:\/\/doi.org\/10.1007\/s11904-007-0020-y","DOI":"10.1007\/s11904-007-0020-y"},{"issue":"1","key":"751_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12879-024-10414-z","volume":"25","author":"V Ogello","year":"2025","unstructured":"Ogello V, Mwangi P, Kwena Z, et al. Preferences for and acceptability of long-acting HIV prevention products among pregnant and lactating women accessing health services in kenya: a mixed method cross-sectional analysis. BMC Infect Dis. 2025;25(1):37. https:\/\/doi.org\/10.1186\/s12879-024-10414-z.","journal-title":"BMC Infect Dis"},{"key":"751_CR70","unstructured":"Tim Williamson. The Impact of Depo-Provera on an Individual\u2019s Mental Health. Psychreg. December 20. 2024. Accessed March 22, 2025. https:\/\/www.psychreg.org\/impact-depo-provera-individual-mental-health\/"},{"issue":"1","key":"751_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/COH.0000000000000776","volume":"18","author":"AD Kerkhoff","year":"2023","unstructured":"Kerkhoff AD, Muiruri C, Geng EH, Hickey MD. A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment. Curr Opin HIV AIDS. 2023;18(1):32\u201345. https:\/\/doi.org\/10.1097\/COH.0000000000000776.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"751_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/COH.0000000000000895","volume":"20","author":"D Joseph Davey","year":"2025","unstructured":"Joseph Davey D, Dadan S, Wara N. Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings. Curr Opin HIV AIDS. 2025;20(1):32\u20138. https:\/\/doi.org\/10.1097\/COH.0000000000000895.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"751_CR73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10461-024-04529-2","volume":"29","author":"W Makoni","year":"2025","unstructured":"Makoni W, Lorenzetti L, Mancuso N, et al. HIV prevention product acceptability and preference among women in Sub-Saharan Africa to inform novel biomedical options in development: A systematic review. AIDS Behav. 2025;29(1):257\u201393. https:\/\/doi.org\/10.1007\/s10461-024-04529-2.","journal-title":"AIDS Behav"},{"issue":"9","key":"751_CR74","doi-asserted-by":"publisher","first-page":"e26007","DOI":"10.1002\/jia2.26007","volume":"25","author":"LM Hill","year":"2022","unstructured":"Hill LM, Golin CE, Saidi F, et al. Understanding PrEP decision making among pregnant women in lilongwe, malawi: A mixed-methods study. J Int AIDS Soc. 2022;25(9):e26007. https:\/\/doi.org\/10.1002\/jia2.26007.","journal-title":"J Int AIDS Soc"},{"key":"751_CR75","unstructured":"Hill L. et.al. UNCPM 22323 - Supporting Oral Pre-Exposure Prophylaxis Decision Making Among Pregnant Women in Lilongwe, Malawi: A Pilot Study. clinicaltrials.gov; 2025. Accessed March 30, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06394323"},{"key":"751_CR76","doi-asserted-by":"publisher","unstructured":"Hunt B, Pham A, Glick N, et al. A universal approach to educating patients with HIV about Long-Acting injectable treatment for HIV. AIDS behav. Published Online March. 2025;3. https:\/\/doi.org\/10.1007\/s10461-024-04610-w.","DOI":"10.1007\/s10461-024-04610-w"},{"issue":"10","key":"751_CR77","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jama.2022.0420","volume":"327","author":"JM Sharfstein","year":"2022","unstructured":"Sharfstein JM, Killelea A, Dangerfield D. Long-Acting cabotegravir for HIV prevention: issues of access, cost, and equity. JAMA. 2022;327(10):921\u20132. https:\/\/doi.org\/10.1001\/jama.2022.0420.","journal-title":"JAMA"},{"issue":"12","key":"751_CR78","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1016\/S2352-3018(22)00251-X","volume":"9","author":"L Jamieson","year":"2022","unstructured":"Jamieson L, Johnson LF, Nichols BE, et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022;9(12):e857\u201367. https:\/\/doi.org\/10.1016\/S2352-3018(22)00251-X.","journal-title":"Lancet HIV"},{"issue":"11","key":"751_CR79","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1093\/jac\/dkae305","volume":"79","author":"A Hill","year":"2024","unstructured":"Hill A, Levi J, Fairhead C, et al. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. J Antimicrob Chemother. 2024;79(11):2906\u201315. https:\/\/doi.org\/10.1093\/jac\/dkae305.","journal-title":"J Antimicrob Chemother"},{"key":"751_CR80","doi-asserted-by":"publisher","unstructured":"Wu L, Kaftan D, Wittenauer R, et al. Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis. Lancet HIV.2024;11(11):e765-e773. https:\/\/doi.org\/10.1016\/S2352-3018(24)00239-X","DOI":"10.1016\/S2352-3018(24)00239-X"},{"key":"751_CR81","doi-asserted-by":"publisher","unstructured":"Kaftan D, Sharma M, Resar D, et al. Cost thresholds for anticipated long-actingHIV pre-exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study. J Int AIDS Soc. 2025;28(2):e26427. https:\/\/doi.org\/10.1002\/jia2.26427","DOI":"10.1002\/jia2.26427"},{"key":"751_CR82","doi-asserted-by":"publisher","unstructured":"Davey DJ, Jamieson L. Cost-effectiveness of lenacapavir for PrEP in Africa. Lancet HIV. 2024;11(11):e722-e723. https:\/\/doi.org\/10.1016\/S2352-3018(24)00242-X","DOI":"10.1016\/S2352-3018(24)00242-X"},{"key":"751_CR83","unstructured":"Yeo Y-R WK, Takarinda K, Sithole N, Gwavavy E, Khabo BB, et al. Cost-effectiveness of different risk-group targeting across3 types of PrEP in Zimbabwe. Conference on Retroviruses and Opportunistic Infections; 9\u201312 March; San Francisco, California, 2025."},{"issue":"2","key":"751_CR84","doi-asserted-by":"publisher","first-page":"e26423","DOI":"10.1002\/jia2.26423","volume":"28","author":"E Lankiewicz","year":"2025","unstructured":"Lankiewicz E, Sharp A, Drake P, et al. Early impacts of the PEPFAR stop-work order: a rapid assessment. J Int AIDS Soc. 2025;28(2):e26423. https:\/\/doi.org\/10.1002\/jia2.26423.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"751_CR85","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1016\/S2352-3018(19)30270-X","volume":"6","author":"TL Hiv","year":"2019","unstructured":"Hiv TL. A lesson to learn from dolutegravir roll-out. Lancet HIV. 2019;6(9):e559. https:\/\/doi.org\/10.1016\/S2352-3018(19)30270-X.","journal-title":"Lancet HIV"},{"key":"751_CR86","unstructured":"PrEPWatch. Overall Impact of the Stop Work Order. PrEPWatch. Accessed March 22, 2025. https:\/\/www.prepwatch.org\/impact-overview\/"},{"key":"751_CR87","unstructured":"Kates J, Michaud J, Moss K, Dawson L, Published AR. Overview of President Trump\u2019s Executive Actions on Global Health. KFF. July 9, 2025. Accessed July 21, 2025.  https:\/\/www.kff.org\/global-health-policy\/fact-sheet\/overview-of-president-trumps-executive-actions-on-global-health\/"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00751-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00751-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00751-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:03:13Z","timestamp":1769608993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00751-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00751-2","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"13 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"44"}}